Management Presentation

Condential 2
Company Overview
Strong progress since inception
Oct, 2012
Nov, 2012
Signs agreement for
commercialization of
ChondroCelect
Stallergenes SA and
Genpharm Services extend
collaboration to Egypt
Signs promotional
agreement for Stallergenes
AIT treatments in the UAE
Genpharm starts
operations
April, 2012
Signs commercialization
and distribution agreement
for PrenaTest
Dec, 2012
Feb, 2013
Signs commercializaton
agreement with Genzyme
for Aubagio in MS
Apr, 2013
Sponsors orphan drug
meeting in Washington
DC, US
Apr, 2013
Multiple-year agreement
with Aegerion
Pharmaceutical
Jun, 2013
Holds ASPIRE
event for MENA
Neurologists
Oct, 2013
Sponsors orphan
drug meeting
Geneva
Nov, 2013
Condential 3
Company Overview
Business overview
Overview
Algeria
Libya
Egypt Saudi
Arabia
Yemen
Oman
Morocco
Iran
Womens
Health
Immunology &
Infectious Disease
Neurology Rare Disease
Specialty Therapeutic Focus
! Genpharm is a specialty pharmaceutical
marketing and consulting company
focused on niche therapeutics and
diagnostics for rare disease
! It provides fast and sustainable market
access into the MENA (Middle East &
North Africa) region to its strategic
partners including regulatory and
medical
! It provides Business Development and
market analysis for companies looking to
evaluate the potential of their portfolio in
MENA.
! It acts as the representative agent for
rare disease, biotech and specialty
pharma companies looking to enter or to
expand in the MENA
Algeria
Libya
Egypt
Saudi
Arabia
Morocco Iran
Tunisia Syria
Lebanon
Jordan
Iraq
Yemen
UAE
(Dubai, Headquarter)
Kuwait
Bahrain
Qatar
MENA
Geographical Presence
Condential 4
Company Overview
Mission, Vision & Values
To provide healthcare
organizations with innovative
therapeutic solutions in niche
and rare genetic disease areas,
market access strategies and
sustainable commercial
solutions,
while improving patient care
and quality of life in the Middle
East and North Africa.
We strive to be the partner of
choice for multinational
healthcare
and pharmaceutical companies
expanding into the Middle East
and North Africa region.

We aim to consistently
differentiate ourselves by
serving all of our stakeholders
through evidence based
medicine.
Our Vision Mission Statement
Patient Care
We are dedicated
to patient care
and quality of life
Integrity
We act honestly,
with inclusivity
and respect
Innovation
We offer unique
and sustainable
solutions
Accountability
We are
committed,
reliable and
results focused
Teamwork
We are positive,
professional and
transparent
Iran
Core Values
Condential 5
Company Overview
!Identify business potential for
the product portfolio
!Registration and fast-track
market access strategies
!Raise disease awareness
!Secure funding
!Stakeholders management
!Competent & trained sales
force
!Evidence based medicine
!Advocacy building & KOL
management
!Scientic publications &
events
!Vast network of trusted and
experienced importers/
distributors
!Solid nancial background
!Ensures geographic reach
!Ensures adapted distribution
channels to the product
portfolio
MARKET ACCESS
SCIENTIFIC DIFFERENTIATION DISTRIBUTION & PARTNERSHIP
Genpharms Pillars
Condential 6
Company Overview
Products & services overview
Aubagio Juxtapid Staloral NIOX
Sustainable market access solutions that provide long-term value
ChondroCelect NIPT PrenaTest
Consultancy Specialty Pharma
! Identify business potential
! Recommend appropriate business & operations models
! Recommend strategy & organization
! Formulate adapted market access strategies
! Registration
! Marketing, Promotion & sales force effectiveness
! Fast track market penetration through NPS
! Importation & distribution & Tender participation
! Medical & PV services
Current Partners and Products
Genpharm Services
Global Pharmaceutical Manufacturers
Condential 7
! Aubagio is an FDA & EMA approved once-daily oral tablet, developed by Genzyme, A Sano
Company, that offers an effective alternative for patients suffering from Relapsing Multiple Sclerosis
(RMS)
! Genzyme has partnered with Genpharm to commercialize Aubagio in the MENA region
! Juxtapid is an oral inhibitor of the microsomal triglyceride transfer protein (MTP) and is specically
indicated as an adjunct to a low-fat diet and other lipid-lowering treatments
! Aegerion Pharmaceuticals partnered with Genpharm to commercialize Juxtapid (Lomitapide) in the
Levant region
! Staloral is a sublingual product for patients suffering from moderate to severe allergic rhinitis and/or
mild to moderate allergic asthma
! Stallergenes has partnered with Genpharm to commercialize Staloral in U.A.E and Egypt
! NIOX, developed and distributed by Aerocrine/Stallergenes, is the rst point-of-care medical device
for measuring Fractional Exhaled Nitric Oxide (FeNO)
! Stallergenes partnered with Genpharm to commercialize NIOX in the U.A.E
! ChondroCelect is the only approved somatic cell therapy product from TiGenix, Belgium for repair of
cartilage lesions in the knee using characterized viable autologous cartilage cells
! TiGenix NV partnered with Genpharm for commercialization of ChondroCelect in the GCC and
Levant region
! PrenaTest is the rst Non Invasive Prenatal Diagnostic (NIPD) developed by LifeCodexx in Germany
for the detection of Downs syndrome, Edwards Syndrome and Patau Syndrome
! LifeCodexx AG partnered with BioGen Medical and Genpharm for the commercialization and
distribution of PrenaTest in Turkey, the Middle East and Gulf regions
Portfolio overview
Company Overview
Condential 8
GENPHARM
! MENAs fast growing economy
! High GDP per capita levels
! Rising income levels, increase in literacy levels,
higher healthcare spend by government

Strong MENA
Macro
Background

! Middle East markets are expected to
grow from #12bn in 2012 to #19
bn in 2017, 12-14% growth is among
the highest in the world
Supportive MENA
Pharmaceutical
Market
! Genpharm has strong and
high-prole board of non-
executive members that
bring along comprehensive
experience
Senior Non-Exec
Board
! Genpharm has an experienced
management team and extensive
network with key stakeholders

Strong
Management
Team

Key Highlights
! Genpharm operates in fast growing Orphan drug
market that is expected to reach # 93 bn by
2018, while there are ~2.8 mn people in the
Middle East that are affected by rare disease

Targeted and
Focused
Positioning

Condential 9
7,572
28,633
30,611
37,805
1,097
4,439
8,305
10,457
5,892
2,275
3,567
4,610
5,270
7,539
17,223
17,931
18,540
32,007
35,653
76,595
Global
UK
Germany
US
India
China
Brazil
Russia
MENA
Egypt
Jordan
Iraq
Iran
Lebanon
Bahrain
KSA
Oman
UAE
Kuwait
Qatar
GDP per capita #, 2012
MENA population growth to outpace other economic groups
Strong MENA Macro Background
2.0%
0.8%
0.7%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
MENA Countries Developing Countries Developed Countries
Top Countries
where
Genpharm
Operates
Developed
Economies
Developing
Economies
Population Growth (CAGR 2013-2018)
390
491
346
-
100
200
300
400
500
600
MENA Total Top 5 European
Countries
North America
Population, 2012 (mn)
Source: IMF Data
Note: Developing Countries - China, India, Brazil & Russia; Developed Countries - US, Germany, UK & Canada; North America - US & Canada; KSA stands for Saudi Arabia; Top 5 European Countries - Germany, France, Italy, Spain, & Netherlands
MENA Countries - Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, UAE & Yemen; Conversion rate used across slides: 1 US$ = # 0.73118
2
11
17
30
31
33
66
78
87
99
123
48
62
89
143
10
21
23
#
Rank out of 188
countries
Condential 10
Strong MENA Macro Background
7.2%
6.1%
5.0%
4.2% 4.2% 4.0%
3.8%
3.8%
3.7%
3.6%
3.5%
3.2%
2.8%
1.4%
4.1%
7.1%
5.8%
3.1%
3.1%
2.9%
1.9%
1.2%
3.8%
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
7.0%
8.0%
I
r
a
q

Q
a
t
a
r

M
o
r
o
c
c
o

K
S
A

T
u
n
i
s
i
a

J
o
r
d
a
n

O
m
a
n

B
a
h
r
a
i
n

U
A
E

A
l
g
e
r
i
a

E
g
y
p
t

L
e
b
a
n
o
n

K
u
w
a
i
t

I
r
a
n

M
E
N
A

C
h
i
n
a

I
n
d
i
a

R
u
s
s
i
a

B
r
a
z
i
l

U
S

U
K

G
e
r
m
a
n
y

G
l
o
b
a
l

Average GDP Growth (2013-2018)
Strong GDP growth provides an upside to healthcare spend
Health expenditure
per capita: # 394
Health expenditure
% of GDP:
4.6%
Health expenditure
per capita: # 103
Health expenditure
% of GDP:
3.9%
Health expenditure
per capita: # 316
Health expenditure
% of GDP:
5.2%
Health expenditure
per capita: # 6,294
Health expenditure
% of GDP:
17.9%
MENA
1
India China
United States
Source: IMF, World Bank
Note: (1) MENA comprises Arab World and Iran; Health Expenditure - Data is for 2011, Healthcare expenditure per capita PPP (constant 2005 international $ converted to Euro)
Western Europe
Size: # 128-150 bn
CAGR (2013-17): -2% to 4%
Middle East
Size: # 12-19 bn
CAGR (2013-17): 12% to 14%
Africa
Size: # 19-26 bn
CAGR (2013-17): 7% to 10%
Central & Eastern Europe
Size: # 48-56 bn
CAGR (2013-17): 4% to 7%
Asia Pacic
Size: # 202-216 bn
CAGR (2013-17): 12% to 15%
North America
Size: # 276-298 bn
CAGR (2013-17): 1% to 4%
Latin America
Size: # 71-78 bn
CAGR (2013-17): 10% to 13%
Supportive MENA Pharmaceutical Market
Middle East is one of the fastest growing pharma markets
11
Low Growth
(< 4%)
High-Mid Growth
(7% to 13%)
High Growth
(12% to 15%)
Low-Mid Growth
(4% to 7%)
Source: IMS Market Prognosis, Apr 2013
Note: Western Europe includes EU5 and rest of Western Europe; Size: 2013-2017, CAGR is between 2013-2017
Condential
Condential 12
Genpharm is well positioned inthe nichemarket segments
Rare Disease
! It is a type of disease that inuence a small percentage of population
! Majority rare diseases are genetic and have an impact on an individual throughout their life, even if
symptoms do not immediately appear
! These type of diseases appear in early life and near about ~30% children die within rst 5 years
Orphan Drugs
! An orphan drug is a pharmaceutical agent that has been developed specically to treat a rare medical
condition, the condition itself being referred to as an orphan disease
! The development of orphan drugs has been nancially incentivized through US law via the Orphan Drug
Act of 1983
! The National Organization for Rare Disorders (NORD) estimates 30 million Americans suffer from 7,000
rare diseases. In the MENA regions estimates are around 2.8mio sufferers
! To date, 425 indication designations covering 347 drugs have been approved
! Global market for orphan drug is estimated at # 65.8 bn with US dominating with ~50% share
! Highly fragmented market for orphan drug is estimated to grow at a CAGR of ~7% through 2013-2018
! Top 10 largest orphan drugs manufacturing companies account for ~33% share of global market
! Strong local presence and market knowledge along with good legal relations act a catalyst in this
organization
! These drugs have exclusive market rights with least competitive drug prices (10 in the EU and 7 in the
US)
! Orphan drugs fall under low volume and high price category
Specialty drugs
! These are the drugs that are used to treat medical conditions including multiple sclerosis, hemophilia,
hepatitis and rheumatoid arthritis
! These forms the part of rapidly growing drugs category that are the result of sustained advances in drug
development technology
! Specialty drugs are mostly injectable or infused medicines, but may also include oral medicines
! These are expensive with limited access with sometimes complicated treatment and compliance issues
Targeted and Focused Positioning for
Genpharm
Condential 13
59%
42%
32%
34%
38% 40%
34%
49%
55%
56%
52% 48%
6% 8%
10% 8% 8% 10%
1% 1% 3% 1% 2% 2%
0%
20%
40%
60%
80%
100%
UAE KSA Egypt Jordan Morocco Tunisia
Segment Value by Country
Original Brands Branded Generics Others Unbranded Generics
Targeted and Focused Positioning for
Genpharm
Genpharm is purposely positioned in the original brands market
Unbranded
Generics
Branded
Generics
Unprotected
Originals
Protected
widely RX
Niche
Specialty
Commodity Differentiated
! High Volume & Low
Margin
! Tight Control of Cost
! Focus on Supply Chain
! Purchasing professionals
are the key stakeholders
! Promote price and
service
! Seek scale to gain cost
efciencies and market
power
! Lower Volume & High
Margin
! Emphasis on Quality
! Focus across a complex
set of stakeholders
! Promote efcacy, safety,
tolerability
! Seek differentiation to
drive demand
Business Model Characteristics for different product types
30%
27%
22%
18%
27%
18%
57% 61%
60%
61%
54%
52%
12% 12%
16%
18%
17%
29%
2%
1% 2% 3% 2% 2%
0%
20%
40%
60%
80%
100%
UAE KSA Egypt Jordan Morocco Tunisia
Segment Volume by Country
Original Brands Branded Generics Others Unbranded Generics
Source: IMS MIDAS June 2012, Licensing Data, Rx bound
Note: RX = Protected Formula/Product
Condential 14
and in the orphan drug market which is consistently outgrowing the
non orphan drug market
Targeted and Focused Positioning for
Genpharm
24.1
27.8
33.6
40.9
44.6
50.5
57.0
60.7
65.8
70.2
76.0
80.4
86.3
92.9
18%
15%
21%
22%
9%
13% 13%
6%
8%
7%
8%
6%
7%
8%
8%
8%
9%
7%
2%
1%
5%
-3%
0%
3%
4%
4%
4%
3%
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018
Global Orphan Drug Sales (#bn) Global Orphan Drugs Growth Global Non-Orphan Drugs Growth
Source: EvaluatePharma, April 2013
! The rare disease drugs are highly priced
due to their research and development
cost. Customers are typically government
hospitals and similar institutions with a
substantial budget for their patients.
Condential 15
[!]
Fast track
Registrations
Limited Number
Of Prescribers /
Physicians
Institutional
Customers

Named Patient
Sales
High Value
Products
Genpharm is well positioned in market segments that offer a number of
attractive commercial characteristics:
! Genpharm operates in the niche,
rare disease/Orphan Drug markets
where the number of patients and
prescribing physicians is limited
! Innovative products for unmet medical
needs are given fast approval and
reimbursement pathway
! Robust local expertise & knowledge of
the local processes
! Existing network with key decision
maker centers and stakeholders further
helps to market and fast track
registrations
! Genpharm manages all
stakeholders including Physicians,
Patient groups, Payers and
Distributors

! Need of a highly competent,
evidence based selling and
promotion approach through a
limited number of KAMs/MSLs
! For unmet medical needs and specialty therapeutic, products can be
purchased on a Name Patient Sales basis prior to registration.
! Fast track market access and market penetration. Early sales upside
Targeted and Focused Positioning for
Genpharm
Condential 16
Strong Management Team (1/2)
! 14 years of regional experience in
Senior Executive roles in the Pharma
industry
! Launched and managed operations for
several Biotech and rare disease products
including (go to market strategies &
funding)
! Wide expertise and network in emerging
markets, in particular in the Middle East &
North Africa Region as well as in South
East Europe and Russia.
! Active member of several industry
associations and business councils
! Member of the Diplomatic Circle in Geneva
and Public speaker on industry matters
Mr. Karim Smaira,
Co-founder & CEO
! More than 25 years of regional Pharma
experience in Senior Executive roles
within MNCs & Distributors.
! Established and Managed several regional
ofces in MENA
! Pharmaceutical entrepreneur with several
start ups in the region, active member of
several industry associations and business
councils
! Honored by Rotary several times as Paul
Harris Fellow for meeting outstanding
personal, professional standards and
charitable work.
! Several awards recognizing successful
businesses in MENA
Mr. Kamel Ghammachi,
Co-founder & Managing Partner
Condential 17
Mr. Karim Smaira,
Co-founder & CEO
Mr. Kamel Ghammachi,
Co-founder & Managing Partner
Strong Management Team (2/2)
Yassin Taha,
Market Access
Mohamed Nabil Al-Nayeb,
Sales
Dalia Kamal,
Marketing
Magdy Makram,
Commercial Operations
Ashwathy Anil,
Business Development
Condential 18
! CEO NextPharma
! Former Deputy CEO
Merck-Serono, Executive
Vice President
International and
emerging markets Merck-
Serono
! Former Head of product
development at
SERONO
! CEO of Emirates NBD;
the largest regional
bank by Assets
! Board Director Emirates
Islamic Bank
! Head of Corporate
Banking HSBC Middle
East; President and CEO
of HSBC Korea
! Director in Emirates Fund
Managers (Jersey)
Limited, and a founder
member of Visa CEMEA
Advisory Forum
! Chairman of the
Cigalah group, a leading
pharmaceutical company
and distributor in KSA &
part of the Naghi holding
! Founding member of the
Swiss Arab Postgraduate
Clinical Acedemy
(SAPCA in 2010)
! Board Member of several
industrial and business
groups in KSA
! Founding Partner &
Managing Director of
Genyx LLC
consultancy,
specializing in
management consulting,
staff engagement and
alignment, employee
assessment, senior
executive coaching in
several industries
including Pharma.
! Former Vice President of
Pearson Higher
Education, UK
! Former Vice President of
Nelsom Education,
Canada
Mr. Franck
Latrille
Mr. Rick
Pudner
Sheikh Yasser
Naghi
Mr. Dave
Dimmell
Senior Non-Executive Board
For enquiries and contact:



Dubai Biotechnology & Research Park
P.O. Box 8145
Dubai, United Arab Emirates
Tel: +971 4 4227010

info@genpharmservices.com
www.genpharmservices.com

!"#$% &"!